Anika Therapeutics' (NASDAQ:ANIK) stock falls as the company's cartilage repair product Hyalofast misses key trial endpoints ...

Shares of Anika Therapeutics hit a 52-week low after it said its Hyalofast cartilage-repair product didn't meet its co-primary endpoints in a Phase III study. The stock was recently down 24% to $8.43 ...

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the ...

The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.